Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Gilead applies for PrEP approval in Canada

Gilead has applied to Health Canada for Truvada to be approved as PrEP – HIV pre-exposure prophylaxis. Truvada is not approved as PrEP yet in Canada which means doctors must prescribe it off-label and it is not yet on any provincial drug plan formularies outside of Quebec. Gilead Pharmaceuticals has now formally submitted its application to Health Canada for Truvada to also be approved for a preventative indication. Much of this can be attributed to a petition launched in April by several HIV and gay men’s health organizations in Canada, calling on Gilead to apply to Health Canada.

Published
27 August 2015
From
Homoculture.ca
Hepatitis C treatment: Back to the warehouse

Like many physicians that specialize in hepatitis C virus (HCV) treatment, I have spent the last few years advising many of my patients with chronic HCV infection to defer treatment and wait for new therapies. Patients, advocacy groups, and physicians closely followed the development of [these new therapies] in eager anticipation of US Food and Drug Administration (FDA) approval and, for most patients, the possibility of a cure of their HCV infection. However, this eager anticipation morphed into uneasy concern as, along with FDA approval, drug pricing was announced.

Published
26 August 2015
From
Clinical Liver Disease
European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company’s Marketing Authorization Application (MAA) for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg (R/F/TAF) has been fully validated and is now under evaluation by the European Medicines Agency (EMA).

Published
21 August 2015
From
Gilead press release
After Curing Hepatitis C, Gilead Works to Vanquish More Viruses

Gilead Sciences Inc., basking in the success of its cure for hepatitis C, is setting ambitious goals to vanquish two other major viral scourges: HIV and hepatitis B.

Published
19 August 2015
From
Bloomberg
HIV drug ad encourages patient engagement, social media

Patient engagement is one of the big buzzwords in healthcare of late, getting at least lip service from providers nationwide. Now, with a touch of social media, it’s finding its way into pharmaceutical marketing.

Published
18 August 2015
From
MedCity News
Medicines Patent Pool At 5 Years: Promises Kept, Changes Ahead – An Interview With Greg Perry

The Medicines Patent Pool in Geneva is celebrating five years of existence this month. MPP Executive Director Greg Perry sat down with Intellectual Property Watch Catherine Saez to describe progress made since its inception, the success of its licensing agreement model, and plans for the future, including a possible extension to other diseases such as tuberculosis and hepatitis C.

Published
04 August 2015
From
Intellectual Property Watch
GSK flags up pipeline as HIV drugs help it beat profit forecasts

GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts.

Published
30 July 2015
From
Reuters
Gilead Profit Tops Estimates as Hepatitis C Drug Sales Surge

Gilead Sciences Inc., maker of the hepatitis C drugs Sovaldi and Harvoni, posted second-quarter profit that topped analysts’ estimates as revenue surged. Gilead raised its sales forecast for the year.

Published
30 July 2015
From
Bloomberg
Gilead Limits Enrollment in its Hep C Patient Program to Pressure Insurers

In a bid to push back against payers, Gilead Sciences is limiting enrollment to its patient assistance program for hepatitis C drugs, which helps people obtain the Sovaldi and Harvoni treatments when they lack sufficient insurance coverage or the financial wherewithal to get the medicines otherwise.

Published
20 July 2015
From
Wall Street Journal Pharmalot blog
TAG Pipeline Report

2015 report on the pipeline for new HIV, HCV and TB drugs.

Published
17 July 2015
From
TAG
← First12345...79Next →

Filter by country